The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2019 | Consolidation therapy options for myeloma post-transplant
The benefits of consolidation therapy for patients having had hematopoietic stem cell transplantation for multiple myeloma (MM) are still controversial. Philip McCarthy, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, compares data from the EMN02 (NCT01208766) and BMT CTN 0702 (NCT01109004 ) trials with regards to consolidation therapy. McCarthy highlights that both trials suggest high risk patients may require “something more”, additionally that an ancillary study of BMT CTN 0702 , BMT CTN PRIMeR, aims to understand this further. Secondly, Prof. McCarthy discusses using ixazomib, lenalidomide and daratumumab for maintenance, both individually and in combination. Finally, Prof. McCarthy discusses the importance of defining an early endpoint, this would help drive the field forward in understanding and developing new therapies for MM.
